HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro.

Abstract
Organometallic ruthenium-arene compounds bearing a maltol ligand have been shown to be nearly inactive in in vitro anticancer assays, presumably due to the formation of dimeric Ru(II) species in aqueous solutions. In an attempt to stabilize such complexes, [Ru(eta(6)-p-cymene)(XY)Cl] (XY=pyrones or thiopyrones) complexes with different substitution pattern of the (thio)pyrone ligands have been synthesized, their structures characterized spectroscopically, and their aquation behavior investigated as well as their tumor-inhibiting potency. The aquation behavior of pyrone systems with electron-donating substituents and of thiopyrone complexes was found to be significantly different from that of the maltol-type complex reported previously. However, the formation of the dimer can be excluded as the primary reason for the inactivity of the complex because some of the stable compounds are not active in cancer cell lines either. In contrast, studies of their reactivity towards amino acids demonstrate different reactivities of the pyrone and thiopyrone complexes, and the higher stability of the latter probably renders them active against human tumor cells.
AuthorsWolfgang Kandioller, Christian G Hartinger, Alexey A Nazarov, Caroline Bartel, Matthias Skocic, Michael A Jakupec, Vladimir B Arion, Bernhard K Keppler
JournalChemistry (Weinheim an der Bergstrasse, Germany) (Chemistry) Vol. 15 Issue 45 Pg. 12283-91 (Nov 16 2009) ISSN: 1521-3765 [Electronic] Germany
PMID19821465 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Ligands
  • Organometallic Compounds
  • Pyrones
  • Ruthenium Compounds
  • maltol
Topics
  • Antineoplastic Agents (chemistry, pharmacology)
  • Cell Line, Tumor
  • Crystallography, X-Ray
  • Drug Screening Assays, Antitumor
  • Humans
  • Ligands
  • Molecular Structure
  • Organometallic Compounds (chemistry, pharmacology)
  • Pyrones (chemistry, pharmacology)
  • Ruthenium Compounds (chemistry, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: